Esperante Ventures is a Hoofddorp, Netherlands based venture capital firm. They focus on investing in life sciences companies, specifically in drug development, diagnostic and bio-marker tests and pharmaceutical sales.
Esperante Ventures invests between €300,000 to €700,000 for an equity stake of 3% to 33%. They look to deliver for their investments to have management ready to bring the company to financial independence or a liquidity event or exit within five years.
Founded in 2004 as a private investment company, Esperante Ventures is controlled by C&P Group Holdings, a privately controlled life sciences interest group.
Esperante Ventures has made investments in Versantis, Arquer Diagnostics, Oxford Cancer Biomarkers, Cytox, Haemostatix, Anergis, Canbex Therapeutics, Karus Therapeutics, Novacta Biosystems and Cara Therapeutics.
Esperante Ventures exited their investments in Haemostatix, Canbex Therapeutics, Thiakis, Pinnacle Biologics and Cara Therapeutics.
Sandy Primrose, PhD, MBE